7,460 Shares in Gilead Sciences, Inc. $GILD Acquired by Patton Albertson Miller Group LLC

Patton Albertson Miller Group LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, HoldingsChannel reports. The firm bought 7,460 shares of the biopharmaceutical company’s stock, valued at approximately $828,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Csenge Advisory Group grew its position in Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after acquiring an additional 16,288 shares during the period. Railway Pension Investments Ltd lifted its stake in shares of Gilead Sciences by 3.1% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the last quarter. TriaGen Wealth Management LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $1,274,000. iA Global Asset Management Inc. increased its position in shares of Gilead Sciences by 11.6% during the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after purchasing an additional 23,046 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Wolfe Research raised its price target to $155 (from $150) and kept an “outperform” rating — implying ~10% upside from current levels. Wolfe Research PT Raise
• Positive Sentiment: Citigroup published a bullish forecast for strong price appreciation, supporting demand expectations for GILD. Citigroup Forecast
• Positive Sentiment: Truist Financial also issued a forecast calling for meaningful upside, lining up with broader analyst optimism. Truist Forecast
• Positive Sentiment: BMO Capital Markets added to the chorus of bullish forecasts, which reinforces analyst-driven buying interest. BMO Forecast
• Positive Sentiment: UBS reiterated expectations for upside, further supporting consensus that GILD’s fundamentals and pipeline justify higher valuations. UBS Note
• Positive Sentiment: Coverage pieces (BarChart, Zacks interest) note that Gilead has outperformed the market and that analysts are broadly optimistic — positive sentiment that can attract momentum flows. BarChart Analysts Overview
• Neutral Sentiment: Zacks flagged increased investor attention to GILD (tracking user searches), which can boost volume but is not a directional catalyst by itself. Zacks Attention Note
• Neutral Sentiment: Reported short-interest data is inconsistent (entries show increases but list 0 shares / NaN), suggesting a data glitch — no clear short-squeeze or heavy shorting signal from this report.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares at ~$139.89 (?$1.4M), trimming his holding ~1.76%. Insider sales can be read negatively by some investors even if part of routine diversification. SEC Form 4

Wall Street Analyst Weigh In

Several brokerages have weighed in on GILD. HSBC increased their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a report on Tuesday, January 20th. Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Wolfe Research upped their target price on shares of Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Citigroup raised their price target on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $135.56.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the completion of the transaction, the chief executive officer directly owned 556,698 shares of the company’s stock, valued at $77,876,483.22. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 257,397 shares of company stock worth $33,385,512 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $139.55 on Friday. The company’s fifty day moving average is $125.05 and its two-hundred day moving average is $119.38. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm has a market capitalization of $173.14 billion, a P/E ratio of 21.64, a PEG ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $93.37 and a one year high of $141.71.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences’s revenue was up 3.0% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.